- Home
- TNGX vs GERN Comparison
TNGX vs GERN Comparison
Compare TNGX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GERN
- Stock Information
- Founded
- TNGX 2014
- GERN 1990
- Country
- TNGX United States
- GERN United States
- Employees
- TNGX N/A
- GERN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- GERN Health Care
- Exchange
- TNGX Nasdaq
- GERN Nasdaq
- Market Cap
- TNGX 723.2M
- GERN 823.0M
- IPO Year
- TNGX N/A
- GERN 1996
- Fundamental
- Price
- TNGX $8.76
- GERN $1.24
- Analyst Decision
- TNGX Strong Buy
- GERN Buy
- Analyst Count
- TNGX 6
- GERN 7
- Target Price
- TNGX $10.00
- GERN $3.17
- AVG Volume (30 Days)
- TNGX 2.1M
- GERN 7.4M
- Earning Date
- TNGX 11-06-2025
- GERN 11-06-2025
- Dividend Yield
- TNGX N/A
- GERN N/A
- EPS Growth
- TNGX N/A
- GERN N/A
- EPS
- TNGX N/A
- GERN N/A
- Revenue
- TNGX $24,296,000.00
- GERN $164,447,000.00
- Revenue This Year
- TNGX $20.42
- GERN $175.15
- Revenue Next Year
- TNGX N/A
- GERN $56.61
- P/E Ratio
- TNGX N/A
- GERN N/A
- Revenue Growth
- TNGX N/A
- GERN 11877.20
- 52 Week Low
- TNGX $1.03
- GERN $1.09
- 52 Week High
- TNGX $9.70
- GERN $4.50
- Technical
- Relative Strength Index (RSI)
- TNGX 58.17
- GERN 43.96
- Support Level
- TNGX $8.85
- GERN $1.19
- Resistance Level
- TNGX $9.31
- GERN $1.31
- Average True Range (ATR)
- TNGX 0.56
- GERN 0.08
- MACD
- TNGX 0.08
- GERN -0.01
- Stochastic Oscillator
- TNGX 67.60
- GERN 17.24
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.